rhTNFR-Fc
PreclinicalSmall molecule
rhTNFR-Fc is one of 17 small molecule programs targeting Necrosis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Necrosis
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Integrilin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Zoloft
VViatris Specialty LLC
Approved
Avastin
RochePhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Serplulimab
Shanghai Henlius BiotechPhase 2
QRX-3
EEbima Clifford Okundaye
Phase 3
Rocaltrol
Jazz PharmaceuticalsPreclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Actemra
CCelltrion
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rhTNFR-Fc. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLihua Duan